Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9927994 | 0.91 | USP2 (0.38) | HTTUSP2LMNAALDH1A1CYP1A2 | |
| SCHEMBL9928003 | 0.91 | HTT (0.40) | HTTUSP2CYP3A4LPAR5 | |
| SCHEMBL15255243 | 0.90 | USP2 (0.37) | HTTUSP2LMNAALDH1A1CYP1A2 | |
| SCHEMBL61330 | 0.90 | USP2 (0.37) | HTTUSP2LMNAALDH1A1CYP1A2 | |
| SCHEMBL9928006 | 0.88 | USP2 (0.39) | HTTUSP2LMNAALDH1A1LPAR5 | |
| SCHEMBL9928012 | 0.88 | HTT (0.36) | HTT | |
| SCHEMBL9927974 | 0.87 | CYP3A4 (0.50) | HTTUSP2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL16298571 | 0.87 | HTT (0.38) | HTTUSP2CYP2C19 | |
| SCHEMBL60823 | 0.87 | USP2 (0.35) | HTTUSP2LMNAALDH1A1LPAR5 | |
| SCHEMBL61834 | 0.87 | USP2 (0.37) | HTTUSP2LMNAALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944534-B2 | Reducing aluminosilicate scale in the Bayer process | ECOLAB USA INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170050861-A1 | Reducing Aluminosilicate Scale in the Bayer Process | NALCO COMPANY (US) | 2017-02-23 | — | — | US | disclosed |
| US-9487408-B2 | Reducing aluminosilicate scale in the bayer process | NALCO COMPANY (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487408-B2 | Reducing aluminosilicate scale in the bayer process | NALCO COMPANY (US) | 2016-11-08 | — | — | US | disclosed |
| US-8889096-B2 | Reducing aluminosilicate scale in the bayer process | NALCO COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889096-B2 | Reducing aluminosilicate scale in the bayer process | NALCO COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| WO-2013126683-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | NALCO COMPANY (US) | 2013-08-29 | — | — | WO | disclosed |
| US-20120148462-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | ECOLAB USA INC. | 2012-06-14 | — | — | US | disclosed |
| US-20120148462-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | ECOLAB USA INC. | 2012-06-14 | — | — | US | disclosed |
| US-20110212006-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | ECOLAB USA INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110212006-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | ECOLAB USA INC. | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050861-A1 | Reducing Aluminosilicate Scale in the Bayer Process | DSP, SOST, SORD | HTT 2952/4885USP2 2966/4885LMNA 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.